CD8 T-cell activation occurs 24 hours post-AAV administration and is driven by muscle promoter specificity

Immune responses against transgene products can compromise AAV-mediated gene transfer. Although several factors influencing this immunogenicity have been described, the early in vivo events driving CD8 + T cell activation remain poorly defined. Here, we examined antigen presentation kinetics following intramuscular AAV administration in mice. Strikingly, viral genomes were detected in draining lymph nodes as early as one hour post-injection, and transgene-derived peptides were presented to CD8 + T cells from day 1, resulting in progressive activation and first cell divisions detected at day 4. Removal of the injection site demonstrated that AAV particles reaching draining lymph nodes within the first hour were sufficient to induce cytotoxic transgene-specific CD8 + T cells. Finally, AAV vectors incorporating different muscle-specific promoters and regulatory sequences were evaluated. Although muscle-specific, all promoters exhibited variable transgene expression in dendritic cells in vitro, correlating with early T-cell activation in vivo; notably, those associated with higher early antigen presentation induced robust T cell response, whereas reduced presentation correlated with absence of CD8 + T cells. These findings reveal an unexpectedly early onset of transgene-derived epitope presentation, modulated by promoter specificity, which critically shapes CD8 + T cell response. This provides a rationale for evaluating and mitigating AAV immunogenicity in gene therapy design.